A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression

International Journal of Neuropsychopharmacology

Volumn 16, Issue 2, 2013, Pages 485-496

  Reinares, María ^a,b   Rosa, Adriane R ^a   Franco, Carolina ^a   Goikolea, José Manuel ^a   Fountoulakis, Kostas ^c   Siamouli, Melina ^c   Gonda, Xenia ^d   Frangou, Sophia ^b   Vieta, Eduard ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Anticonvulsants; antiepileptics; bipolar depression; clinical trials; randomized placebo controlled

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; FLUOXETINE; LAMOTRIGINE; LICARBAZEPINE; OLANZAPINE; OXCARBAZEPINE; PREGABALIN; RETIGABINE; TIAGABINE; VALPROATE SEMISODIUM; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT THERAPY; ATAXIA; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; DECREASED APPETITE; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; HAMILTON SCALE; HEART ATRIUM FIBRILLATION; HUMAN; INCREASED APPETITE; INSOMNIA; LIMB WEAKNESS; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SKIN BRUISING; SLURRED SPEECH; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; TREMOR; WEAKNESS; XEROSTOMIA; YOUNG MANIA RATING SCALE;

ACUTE DISEASE; ANTICONVULSANTS; BIPOLAR DISORDER; DATABASES, FACTUAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84875946823     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000491     Document Type: Review

References (59)

1. Altshuler LL, Post RM, Black DO, Keck Jr. PE, et al. (2006). Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. Journal of Clinical Psychiatry 67, 1551-1560.
2. Amann B, Born C, Crespo JM, Pomarol-Clotet E, et al. (2011). Lamotrigine: when and where does it act in affective disorders? A systematic review. Journal of Psychopharmacology 25, 1289-1294.
3. Angst J, Azorin JM, Bowden CL, Perugi G, et al. (2011). Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Archives of General Psychiatry 68, 791-798.
4. Angst J, Gamma A, Bowden CL, Azorin JM, et al. (2012). Diagnostic criteria for bipolarity based on an international sample of 5, 635 patients with DSM-IV major depressive episodes. European Archives of Psychiatry and Clinical Neuroscience 262, 3-11.
5. Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, et al. (2010). Bipolar depression: overview and commentary. Harvard Review of Psychiatry 18, 143-157.
6. Ballenger JC, Post RM (1980). Carbamazepine in manic-depressive illness: a new treatment. American Journal of Psychiatry 137, 782-790.
7. Bond DJ, Lam RW, Yatham LN (2010). Divalproex sodium vs. placebo in the treatment of acute bipolar depression: a systematic review and meta-Analysis. Journal of Affective Disorders 124, 228-234.
8. Bonnín CM, Mart́inez-Arán A, Torrent C, Pacchiarotti I, et al. (2010) Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a longterm, follow-up study. Journal of Affective Disorders 121, 156-160.
9. Bourin M, Prica C (2007). The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders. Neuroscience and Biobehavioral Reviews 31, 963-975.
10. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, et al. (2000). A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Archives of General Psychiatry 57, 481-489.
11. Bowden CL, Calabrese JR, Sachs G, Yatham LN, et al. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry 60, 392-400.
12. Brown EB, McElroy SL, Keck Jr. PE, Deldar A, et al. (2006). A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination vs. lamotrigine in the treatment of bipolar I depression. Journal of Clinical Psychiatry 67, 1025-1033.
13. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, et al. (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. Journal of Clinical Psychiatry 60, 79-88.
14. Calabrese JR, Bowden CL, Sachs G, Yatham LN, et al. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry 64, 1013-1024.
15. Calabrese JR, Elhaj O, Gajwani P, Gao K (2005). Clinical highlights in bipolar depression: focus on atypical antipsychotics. Journal of Clinical Psychiatry 66 (Suppl. 5), 26-33.
16. Calabrese JR, Huffman RF, White RL, Edwards S, et al. (2008). Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders 10, 323-333.
17. Chang YC, Rapoport SI, Rao JS (2009). Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex. Neurochemical Research 34, 536-541.
18. Davis LL, Bartolucci A, Petty F (2005). Divalproex in the treatment of bipolar depression: a placebo-controlled study. Journal of Affective Disorders 85, 259-266.
19. de Dios C, Ezquiaga E, Garcia A, Soler B, et al. (2010). Time spent with symptoms in a cohort of bipolar disorder outpatients in Spain: a prospective, 18-month follow-up study. Journal of Affective Disorders 125, 74-81.
20. Fountoulakis KN (2010). An update of evidence-based treatment of bipolar depression: where do we stand? Current Opinion in Psychiatry 23, 19-24.
21. Fountoulakis KN, Vieta E (2008). Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. International Journal of Neuropsychopharmacology 11, 999-1029.
22. Frey BN, Andreazza AC, Ceresér KM, Martins MR, et al. (2006). Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sciences 79, 281-286.
23. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, et al. (2000). A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology 20, 607-614.
24. Geddes JR, Calabrese JR, Goodwin GM (2009). Lamotrigine for treatment of bipolar depression: independent meta-Analysis and meta-regression of individual patient data from five randomised trials. British Journal of Psychiatry 194, 4-9.
25. Ghaemi SN, Gilmer WS, Goldberg JF, Zablotsky B, et al. (2007). Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. Journal of Clinical Psychiatry 68, 1840-1844.
26. Gitlin MJ, Mintz J, Sokolski K, Hammen C, et al. (2011). Subsyndromal depressive symptoms after symptomatic recovery from mania are associated with delayed functional recovery. Journal of Clinical Psychiatry 72, 692-697.
27. Grunze H, Vieta E, Goodwin GM, Bowden C, et al. (2010). The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2010 on the treatment of acute bipolar depression. World Journal of Biological Psychiatry 11, 81-109.
28. Goodwin GM; Consensus Group of the British Association for Psychopharmacology (2009). Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 23, 346-388.
29. Gyulai L, Bowden CL, McElroy SL, Calabrese JR, et al. (2003). Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28, 1374-1382.
30. Judd LL, Akiskal HS, Schettler PJ, Coryell W, et al. (2003). A prospective investigation of the natural history of the longterm weekly symptomatic status of bipolar II disorder. Archives of General Psychiatry 60, 261-269.
31. Judd LL, Akiskal HS, Schettler PJ, Endicott J, et al. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 59, 530-537.
32. Kasper S, Calabrese JR, Johnson G, Tajima O, et al. (2008). International Consensus Group on the Evidence-Based Pharmacological Treatment of Bipolar I and II Depression. Journal of Clinical Psychiatry 69, 1632-1646.
33. Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, et al. (1999). Metabolism and excretion of mood stabilizers and new anticonvulsants. Cellular and Molecular Neurobiology 19, 511-532.
34. McIntyre RS, Mancini DA, McCann S, Srinivasan J, et al. (2002). Topiramate vs. bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disorders 4, 207-213.
35. MacQueen GM, Young LT, Robb JC, Marriott M, et al. (2000). Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatrica Scandinavica 101, 374-381.
36. Malhi GS, Adams D, Lampe L, Paton M, et al. (2009). Clinical practice recommendations for bipolar disorder. Acta Psychiatrica Scandinavica 439 (Suppl.), 27-46.
37. Muzina DJ, Gao K, Kemp DE, Khalife S, et al. (2011). Acute efficacy of divalproex sodium vs. placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Psychiatry 72, 813-819.
38. National Institute for Health and Clinical Excellence (2006). The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. CG 38. London: National Collaborating Centre for Mental Health.
39. Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, et al. (2006). Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. American Journal of Psychiatry 163, 210-216.
40. Nivoli AM, Colom F, Murru A, Pacchiarotti I, et al. (2011). New treatment guidelines for acute bipolar depression: a systematic review. Journal of Affective Disorders 129, 14-26.
41. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, et al. (2006). Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry 163, 217-224.
42. Popovic D, Reinares M, Amann B, Salamero M, et al. (2011). Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology 213, 657-667.
43. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT (1986). Antidepressant effects of carbamazepine. American Journal of Psychiatry 143, 29-34.
44. Rosa AR, Reinares M, Michalak EE, Bonnin CM, et al. (2010). Functional impairment and disability across mood states in bipolar disorder. Value in Health 13, 984-988.
45. Sachs G, Alshuler L, Ketter T, Suppes T, et al. (2001). Divalproex vs. placebo for the treatment of bipolar depression. Presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology, December 9-13, San Juan, Puerto Rico.
46. Saricicek A, Maloney K, Muralidharan A, Ruf B, et al. (2011). Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 72, 744-750.
47. Schaffer A, Zuker P, Levitt A (2006). Randomized, doubleblind pilot trial comparing lamotrigine vs. citalopram for the treatment of bipolar depression. Journal of Affective Disorders 96, 95-99.
48. Smith LA, Cornelius VR, Azorin JM, Perugi G, et al. (2010). Valproate for the treatment of acute bipolar depression: systematic review and meta-Analysis. Journal of Affective Disorders 122, 1-9.
49. Tohen M, Bowden CL, Calabrese JR, Lin D, et al. (2006). Influence of sub-syndromal symptoms after remission from manic or mixed episodes. British Journal of Psychiatry 189, 515-519.
50. Tohen M, Vieta E, Calabrese J, Ketter TA, et al. (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry 60, 1079-1088.
51. van der Loos ML, Mulder PG, Hartong EG, Blom MB, et al. (2009). Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 70, 223-231.
52. van der Loos ML, Mulder P, Hartong EG, Blom MB, et al. (2010). Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatrica Scandinavica 122, 246-254.
53. van der Loos ML, Mulder P, Hartong EG, Blom MB, et al. (2011). Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disorders 13, 111-117.
54. van Lieshout RJ, MacQueen GM (2010). Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review. British Journal of Psychiatry 196, 266-273.
55. Vasudev K, Macritchie K, Geddes J, Watson S, et al. (2006). Topiramate for acute affective episodes in bipolar disorder. Cochrane Database of Systematic Reviews. CD003384. doi:10.1002/14651858.CD003384.pub2.
56. Vieta E, Locklear J, Günther O, Ekman M, et al. (2010). Treatment options for bipolar depression: a systematic review of randomized, controlled trials. Journal of Clinical Psychopharmacology 30, 579-590.
57. Vieta E, Rosa AR (2007). Evolving trends in the long-term treatment of bipolar disorder. World Journal of Biological Psychiatry 8, 4-11.
58. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, et al. (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders 11, 225-255.
59. Zhang ZJ, Kang WH, Tan QR, Li Q, et al. (2007). Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. Journal of Psychiatric Research 41, 360-369.